A new study from Michigan Medicine found that children were more likely to stop using asthma inhalers after the steroid medication Flovent was withdrawn from the market in early 2024. U-M pediatrician Dr. Kao Ping Chua linked the decline to insurance coverage barriers with the generic replacement and changes to Medicaid rebate policies. Published in JAMA, the study highlights growing concerns about reliable, affordable access to asthma treatment for children.
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.